Welcome To Diurnal

Diurnal is a UK-based specialty pharmaceutical company dedicated to developing hormone therapeutics to aid lifelong treatment for rare and chronic endocrine conditions, including Congenital Adrenal Hyperplasia, Adrenal Insufficiency, Hypogonadism and Hypothyroidism.

The company has a strong, multi-skilled entrepreneurial management team with extensive pharmaceutical product development experience and an affiliated network of world-class clinical experts in the area of endocrinology.

Mission Statement

To address the major unmet clinical and patient needs in endocrinology by creating products for the lifelong treatment of chronic conditions.

Latest News

  • 05 Aug
    2020

    Alkindi® approved in Israel

    Significant market opportunity to address an unmet need in paediatric AI

    Further validates strategy to optimise market access outside of Europe and US

    Read More

  • 30 Jul
    2020

    Business and trading update

    Continued strong sales growth for Alkindi® in key markets
    130% year-on-year revenue growth across Europe

    Read More

  • 30 Jul
    2020

    Positive DITEST™ Regulatory Meeting with US FDA

    FDA endorses 505(b)(2) route for DITEST™

    Read More